Clinical Trials Directory

Trials / Completed

CompletedNCT01331421

Bioequivalency Study of Exemestane 25 mg Tablet Under Fasted Conditions

A Single Dose, 2-Period, 2-Treatment, 2-Way Bioequivalency Study of Exemestane 25 mg Tablets Under Fasting Conditions

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
48 (actual)
Sponsor
Roxane Laboratories · Industry
Sex
Female
Age
18 Years – 55 Years
Healthy volunteers
Accepted

Summary

The objective of this study was to prove the bioequivalence of Exemestane 25 mg tablet under fasted conditions

Conditions

Interventions

TypeNameDescription
DRUGexemestane25 mg tablet

Timeline

Start date
2004-07-01
Primary completion
2004-07-01
Completion
2004-08-01
First posted
2011-04-08
Last updated
2018-01-23

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT01331421. Inclusion in this directory is not an endorsement.